April 2012

To paraphrase Mark Twain, the death of the health insurance industry has been greatly exaggerated. Plans simply have to develop new business models.
Joseph Burns
The UC–Berkeley health care economist says the cost-control and performance-improvement methods we’ve been developing for years can work, but implementing them on a wide scale may come as a last resort
John Marcille
Provenge is just one example of an expensive biotechnology drug whose survival analyses leave much to be desired
John Carroll
Treating sleep apnea greatly reduces global costs, but compliance remains a concern
Frank Diamond


Editor’s Memo
John Marcille
Viewpoint: Employer View
Larry Boress
Viewpoint: Health Plan View
Brad Wilson
Legislation & Regulation
Health plan officials are not doing handstands over the federal government’s extension of a deadline to disclose benefits to members in a readable form
John Carroll
Medication Management
Insurers feel pressure to incorporate new agents into their drug benefit, but evidence of effectiveness is questionable
Thomas Reinke
Evidence Review
A summary of ECRI Institute’s Health Technology Forecast Report
Employers and the federal government like these programs, but some question their cost-effectiveness
Frank Diamond
Tomorrow’s Medicine
There are many genetic mutations attributable to the condition, but Kalydeco can significantly help a specific subpopulation of patients
Thomas Morrow, MD

Our most popular topics on Managedcaremag.com